Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 is a potent and orally active KCNQ2/Q3 potassium channel opener (EC50: 0.38 μM). ICA-27243 also has antiepileptic and anticonvulsant effects.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 232.00 | |
50 mg | In stock | $ 383.00 | |
100 mg | In stock | $ 559.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 is a potent and orally active KCNQ2/Q3 potassium channel opener (EC50: 0.38 μM). ICA-27243 also has antiepileptic and anticonvulsant effects. |
Targets&IC50 | KCNQ2/Q3 K+ channel:0.38 μM (EC50) |
In vitro | ICA-27243 increases both 86Rb+ efflux (EC50 = 0.2 μM) and whole-cell currents in Chinese hamster ovary cells stably expressing heteromultimeric KCNQ2/Q3 channels (EC50 = 0.4 μM). ICA-27243 produces membrane potential hyperpolarization that could be prevented by coadministration with the M-current inhibitors XE-991 and Linopirdine, in SH-SY5Y human neuroblastoma cells [1]. |
In vivo | In the mouse maximal electroshock epilepsy model, ICA-27243 (1-100 mg/kg; oral administration; male CD-1 mice) has anticonvulsant activity (ED50: 8.4 mg/kg)[1]. |
Molecular Weight | 268.65 |
Formula | C12H7ClF2N2O |
CAS No. | 325457-89-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 247 mg/mL (919.41 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ICA-27243 325457-89-4 Membrane transporter/Ion channel Potassium Channel antiepileptic hyperpolarization opener ICA 27243 Inhibitor KcsA ICA27243 inhibit KCNQ3 KCNQ2 anticonvulsant inhibitor